Effect of Verapamil on Blood Sugar, Immunoreactive Insulin (IRI) and Calcium Levels in Normal Subjects
スポンサーリンク
概要
- 論文の詳細を見る
Verapamil, a calcium antagonist, is known to inhibit glucose-induced and sulfonylurea-induced insulin release in vitro. However, there have been no reports on in vivo effects. The effect of verapamil on the peripheral IRI, blood sugar (BS) and calcium levels was investigated in thirteen normal subjects.<BR>Verapamil, 5 mg, given to four subjects intravenously, caused a slight, but not significant, decrease in IRI, IRI/BS at thirty minutes. A fifty grams oral GTT was performed on nine subjects. Two days later, fifty grams of glucose was administered orally with verapamil 40 mg P. O. and 5 mg I. V. to the same subjects, who had been orally pretreated with 200 mg verapamil in the previous two days. Verapamil inhibited the IRI rise significantly at thirty minutes, but had no effect on BS and calcium levels at any time. The BS and IRI peaks were found at sixty minutes with the verapamil load while both peaks were found at thirty minutes during usual GTT.<BR>These findings were consistent with in vitro studies even with the possible lower concentration of verapamil in vivo.
- 一般社団法人 日本糖尿病学会の論文
一般社団法人 日本糖尿病学会 | 論文
- Hyperlipidemia and Analysis of the Use of Lipid-lowering Drugs in Non-insulin-dependent Diabetes Mellitus.
- Thyrotoxic Crisis in a Patient with Mitochondrial Diabetes Mellitus.
- Rapidly Progressive Nephropathy in a Young Patient with Mitochondrial Gene Mutation.
- An Autopsy Case of Ketoacidosis in Insulin Dependent Diabetes Mellitus Patient Complicated with Adult Respiratory Distress Syndrome, DIC and Leukopenia.
- Studies on Alcoholic Beverages in Relation to Body Weight for Mild Diabetics